Comparative Pharmacology
Head-to-head clinical analysis: DEXTROAMPHETAMINE SULFATE versus FOCALIN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROAMPHETAMINE SULFATE versus FOCALIN XR.
DEXTROAMPHETAMINE SULFATE vs FOCALIN XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases extracellular levels of norepinephrine and dopamine by blocking reuptake and promoting release from presynaptic terminals, via trace amine-associated receptor 1 (TAAR1) agonism and vesicular monoamine transporter 2 (VMAT2) inhibition.
Focalin XR (dexmethylphenidate) is a central nervous system stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft. The d-threo enantiomer is pharmacologically active.
5-60 mg/day orally divided every 4-6 hours, starting at 5 mg once or twice daily.
Initial 20 mg orally once daily; may increase in 10-20 mg increments at weekly intervals; maximum 60 mg/day.
None Documented
None Documented
9-11 hours (adults); clinical context: twice-daily dosing achieves steady-state in ~2-3 days.
Terminal half-life: 2-3 hours for immediate-release; 6-8 hours for extended-release (FOCALIN XR)
Primarily renal (30-50% unchanged at acidic pH, less at alkaline pH); ~50% as metabolites (mostly deaminated and hydroxylated); minimal biliary/fecal.
Renal (approximately 90% as unchanged drug and metabolites)
Category D/X
Category C
CNS Stimulant
CNS Stimulant